Systemic Al Amyloidosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for systemic al amyloidosis. 37 active patents protecting 3 drugs from 3+ originators. First major cliff: 2027. Daily refresh.

3
Approved drugs
37
Active US patents
52/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Systemic Al Amyloidosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Baxter 15 patents Generic (originally Merck) 15 patents Shilpa 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating systemic al amyloidosis. Each bar = one year. Y-axis scaled to peak year (9 patents).

2
27
1
28
2
30
2
32
3
34
9
35
7
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Velcade
bortezomib
 Shilpa 7 62 — 2032-11-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11679119 Velcade method of use 70 2042-09-23
11679119 Velcade method of use 70 2042-09-23
11752164 Velcade method of use 70 2042-09-23
11752164 Velcade method of use 70 2042-09-23
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
12150896 Decadron method of use 58 2036-10-07
12144889 Decadron method of use 58 2041-04-26
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
8962572 Velcade formulation 42 2032-11-03

Related